ARCHIVES

Afinitor Increases Overall Survival To 3.5 Years in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

Better Access Key To Higher Survival For African-Americans With Colon Cancer

August 30, 2002

Elevated Baseline Glucose Levels Associated With Higher Cancer Risk

November 25, 2011

Cancer Mmeetings Lister For Next Three Months

February 23, 1996

NCAB To Study Recommendations On Cooperative Groups, Coordination Of NCI Treatment Programs

June 20, 1975

Low-Dose IFN Not Effective Against Melanoma, Study Finds

December 26, 2003

FDA Advisors Debate Ban, Black Box And Status Quo of Power Morcellators

July 25, 2014